Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
About the study
The primary objectives of the study are:
To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time.
To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities
The secondary objectives of the study are:
To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP
To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Key Inclusion Criteria:
- All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
- Willing and able to comply with clinic visits and study-related procedures as per protocol
- Provide informed consent signed by study patient or legally acceptable representative
- Able to understand and complete study-related questionnaires as per protocol
EXCLUSION CRITERIA
Key Exclusion Criteria:
- Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
- Any previous treatment with DUPIXENT® for any condition
- Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol
- Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Chronic Rhinosinusitis With Nasal Polyposis
Age (in years)
18+
Participants needed
1000
Est. Completion Date
Aug 17, 2026
Treatment type
Observational
Sponsor
Regeneron Pharmaceuticals
ClinicalTrials.gov identifier
NCT04959448
Study number
R668-cSNP-2072
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?